Tear proteomics reveals biomarkers for managing lacrimal drainage disorders, suggesting new diagnostic strategies.
Tear proteomics has revealed a reproducible inflammatory and immune signature in lacrimal drainage disorders, positioning tear fluid as a valuable, noninvasive biospecimen for diagnosis, monitoring, and precision-based management. Emerging biomarker panels hold potential to stratify disease severity, predict surgical success, and guide individualized therapy. Future work should prioritize multicenter validation, standardized sampling protocols, and integration with advanced analytical and AI-driven diagnostic platforms.
No takes yet. Share an insight, caveat, or question.
Shams et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: